PTX Prospectus 25/03/19 PRICE SENSITIVE Share PTX Capital Raising Presentation - March 2019 25/03/19 PRICE SENSITIVE Share PTX Prescient Completes Equity Raising to Raise $9.1 Million 25/03/19 PRICE SENSITIVE Share PTX Trading Halt 21/03/19 PRICE SENSITIVE Share PTX Appendix 4D and Half Year Financial Report 21/02/19 PRICE SENSITIVE Share PTX December 2018 Appendix 4C - Quarterly 31/01/19 PRICE SENSITIVE Share PTX Receipt of R&D Tax Rebate 15/01/19 PRICE SENSITIVE Share PTX Interim Durability Analysis of PTX-200 Breast Cancer Study 10/12/18 PRICE SENSITIVE Share PTX September 2018 Appendix 4C - Quarterly 31/10/18 PRICE SENSITIVE Share PTX Pipeline Collaboration for Next Generation Formulations 17/10/18 PRICE SENSITIVE Share PTX Canadian Patent Granted for PTX-200 24/09/18 PRICE SENSITIVE Share PTX Improved manufacturing route for PTX-100 03/09/18 PRICE SENSITIVE Share PTX Appendix 4E and 2018 Annual Report 31/08/18 PRICE SENSITIVE Share PTX PTX-200 AML Study Expanded 30/08/18 PRICE SENSITIVE Share PTX June 2018 Appendix 4C - Quarterly 31/07/18 PRICE SENSITIVE Share PTX US Patent Granted for PTX-200 for Ovarian Cancer Treatment 26/07/18 PRICE SENSITIVE download Created with Sketch. 384.4KB Share PTX March 2018 Appendix 4C - Quarterly 23/04/18 PRICE SENSITIVE Share PTX Response to Aware Query 12/04/18 PRICE SENSITIVE Share PTX PTX-200 Phase 1b Breast Cancer Trial Results 10/04/18 PRICE SENSITIVE Share PTX March 2018 Investor Presentation 19/03/18 PRICE SENSITIVE Share PTX Appendix 4D and Half Year Financial Report 27/02/18 PRICE SENSITIVE Share PTX Receipt of R&D Tax Rebate 01/02/18 PRICE SENSITIVE Share PTX December 2017 Appendix 4C - Quarterly 31/01/18 PRICE SENSITIVE Share PTX Clinical Trial Updates 29/01/18 PRICE SENSITIVE Share PTX Clinical Hold Lifted on PTX-200 Breast Cancer Trial 11/12/17 PRICE SENSITIVE Share PTX PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer 06/11/17 PRICE SENSITIVE Share PTX September 2017 Appendix 4C - Quarterly 27/10/17 PRICE SENSITIVE Share PTX PTX-100 to Re-enter Trials in Hematology Niche 03/10/17 PRICE SENSITIVE Share PTX Prescient to resume AML trial 04/09/17 PRICE SENSITIVE Share PTX Appendix 4E and 2017 Annual Report 29/08/17 PRICE SENSITIVE Share PTX June 2017 Appendix 4C - Quarterly 26/07/17 PRICE SENSITIVE Share PTX Novel PTX-100 Cancer Approach Published in Nature 19/06/17 PRICE SENSITIVE Share PTX Clinical Trial Update 29/05/17 PRICE SENSITIVE Share PTX PTX Broker Presentation 16/05/17 PRICE SENSITIVE Share PTX European Patent Granted for PTX-200 12/05/17 PRICE SENSITIVE Share PTX Kansas University Joins PTX's AML Trial 08/05/17 PRICE SENSITIVE Share PTX FDA Grants Orphan Drug Designation for PTX-200 in AML 01/05/17 PRICE SENSITIVE Share PTX March 2017 Appendix 4C - Quarterly 27/04/17 PRICE SENSITIVE Share PTX Successful Completion of Phase 1b Breast Cancer Trial 06/04/17 PRICE SENSITIVE Share PTX Trading Halt 04/04/17 PRICE SENSITIVE Share PTX Response to ASX Price Query 28/03/17 PRICE SENSITIVE Share PTX Three Additional US Patents Granted 16/03/17 PRICE SENSITIVE Share PTX First Cohort Successfully Completed in Phase 1b/2 AML Trial 08/03/17 PRICE SENSITIVE Share PTX Appendix 4D and Half Year Financial Report 23/02/17 PRICE SENSITIVE Share PTX December 2016 Appendix 4C - Quarterly 25/01/17 PRICE SENSITIVE Share PTX First Patient Dosed on Phase 1b/2 AML Trial 14/12/16 PRICE SENSITIVE Share PTX Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation 08/12/16 PRICE SENSITIVE Share PTX Receipt of R&D Tax Rebate-PTX.AX 02/11/16 PRICE SENSITIVE Share PTX September 2016 Appendix 4C - Quarterly-PTX.AX 28/10/16 PRICE SENSITIVE Share PTX Response to ASX Price Query-PTX.AX 19/10/16 PRICE SENSITIVE Share PTX First patient at Moffitt dosed in Phase 1b/2 breast trial-PTX.AX 26/09/16 PRICE SENSITIVE Share PTX Appendix 4E and 2016 Annual Report-PTX.AX 31/08/16 PRICE SENSITIVE Share PTX USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX 04/08/16 PRICE SENSITIVE Share PTX Change to exercise price of options-PTX.AX 20/07/16 PRICE SENSITIVE Share PTX June 2016 Appendix 4C - Quarterly-PTX.AX 20/07/16 PRICE SENSITIVE Share PTX Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX 15/06/16 PRICE SENSITIVE Share PTX Replacement Entitlement Offer Prospectus-PTX.AX 03/06/16 PRICE SENSITIVE Share PTX Offer Document-PTX.AX 18/05/16 PRICE SENSITIVE Share PTX PTX Secures $7.0M Capital Raising-PTX.AX 18/05/16 PRICE SENSITIVE Share PTX Trading Halt-PTX.AX 16/05/16 PRICE SENSITIVE Share PTX March 2016 Appendix 4C - Quarterly-PTX.AX 21/04/16 PRICE SENSITIVE Share PTX PTX-200 Breast Cancer Trial Progresses 17/02/16 PRICE SENSITIVE Share PTX Steven Yatomi-Clarke Appointed CEO 15/02/16 PRICE SENSITIVE Share PTX December 2015 Appendix 4C - Quarterly 25/01/16 PRICE SENSITIVE Share PTX Response to ASX Price Query 19/01/16 PRICE SENSITIVE Share PTX FDA Allows PTX IND for Leukemia Phase Ib & II Trials 08/01/16 PRICE SENSITIVE Share PTX Additional Placement Raises $1.0 million 25/11/15 PRICE SENSITIVE Share PTX September 2015 Appendix 4C - Quarterly 30/10/15 PRICE SENSITIVE Share PTX SPP Fully Underwritten up to target amount of $1.03 million 29/10/15 PRICE SENSITIVE Share PTX Trading Halt 28/10/15 PRICE SENSITIVE Share PTX Executive Management Change 15/10/15 PRICE SENSITIVE Share PTX Two new Patents granted to Protect Lead Asset PTX-200 31/08/15 PRICE SENSITIVE Share PTX Prescient Appendix 4E and 2015 Annual Report 28/08/15 PRICE SENSITIVE Share PTX PTX-200 Phase 1B/2 Clinical Trial Update 26/08/15 PRICE SENSITIVE Share PTX Proposed Grant of Options to Non-Executive Directors 21/08/15 PRICE SENSITIVE Share PTX June 2015 Appendix 4C - Quarterly 30/07/15 PRICE SENSITIVE Share PTX IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX 29/06/15 PRICE SENSITIVE Share PTX US FDA Reactivates PTX's IND for PTX-100 Breast Cancer Trial 10/06/15 PRICE SENSITIVE Share PTX March 2015 Appendix 4C - Quarterly 29/04/15 PRICE SENSITIVE Share PTX Encouraging Pre-Clinical Data Presented at US Cancer Meeting 21/04/15 PRICE SENSITIVE Share PTX Approval received to transfer IND Sponsorship for PTX-200 01/04/15 PRICE SENSITIVE Share PTX Appendix 4D and Half Year Financial Report 27/02/15 PRICE SENSITIVE Share PTX Prescient Therapeutics Granted Key U.S. Patents 23/02/15 PRICE SENSITIVE Share PTX PTX Acquires Worldwide License for Cancer Biomarker p27 09/02/15 PRICE SENSITIVE Share PTX December 2014 Appendix 4C - quarterly 30/01/15 PRICE SENSITIVE Share
4.0¢
(20min delay)
